Status:
COMPLETED
Galantamine for Cognitive Deficits in Schizophrenia
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Alliance for Research on Schizophrenia and Depression
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine the acute effects of the nicotinic receptor allosteric modulator galantamine (0, 4 and 8 mg) on neurocognitive function in schizophrenic smokers (n=20) versus...
Detailed Description
The proposed study will entail a comprehensive evaluation of the effects of acute doses of the nAChR allosteric modulator galantamine hydrochloride (0, 4 and 8 mg) on neurocognitive measures in schizo...
Eligibility Criteria
Inclusion
- \-
- Schizophrenic smokers (n=20) and schizophrenic nonsmokers (n=10) in these studies (total n=20 subjects) will be:
- Between 18 and 60 years of age,
- Have a Full Scale IQ score \>80.
- Smokers will meet DSM-IV criteria for nicotine dependence, and smoke at least 15 cigarettes per day, with an FTND score at baseline \>5, breath CO \>10, and plasma cotinine \>150 ng/ml.
- Nonsmokers will report a history of never smoking (\<100 cigarettes lifetime) or be abstinent from smoking for at least 6 months prior to randomization, with abstinence biochemically confirmed by CO level \<10 ppm and plasma cotinine \<15 ng/ml.
- Schizophrenic subjects will meet DSM-IV criteria for schizophrenia or schizoaffective disorder, and be on a stable dose of antipsychotic medication for at least three months, with positive symptoms stability as judged by the investigator.
- Subjects must be non-treatment seeking smokers with respect to their nicotine dependence.
Exclusion
- Meet criteria for current abuse or dependence for any other alcohol or substance of abuse within the past 6 months, with the exception of nicotine dependence (smokers) or caffeine (all groups).
- An inability to learn the neuropsychological tasks during the training session.
- History of dementia, other neurological illness (e.g. idiopathic Parkinson's Disease, Epilepsy), or any other acute or chronic medical condition known to significantly influence neurocognitive function, at the discretion of the P.I. and Project Director.
- A history of severe renal or hepatic insufficiency, or a known hypersensitivity to galantamine hydrochloride (Razadyne®).
- For smokers, current use of any tobacco products (chewing tobacco, cigars, nicotine replacement therapies like lozenges, gum, nasal spray, inhaler or patch) besides cigarettes.
- A history of hypotension, or currently taking anti-hypertensive medication.
- Interested in quitting smoking (in which case they will be referred to our smoking cessation treatment study).
- Not capable of giving informed consent for participation in this study.
- Positive urine toxicology screen for any substance of abuse.
- Patients who are pregnant or planning on becoming pregnant.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00463879
Start Date
September 1 2005
End Date
September 1 2007
Last Update
December 12 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Connecticut Mental Health Center, Yale School of Medicine
New Haven, Connecticut, United States, 06519